for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

42.33EUR

Change

-0.17(-0.40%)

Volume

4,219,432

Today's Range

41.51

 - 

42.42

52 Week Range

41.51

 - 

78.34

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
42.50
Open
42.18
Volume
4,219,432
3M AVG Volume
77.29
Today's High
42.42
Today's Low
41.51
52 Week High
78.34
52 Week Low
41.51
Shares Out (MIL)
982.42
Market Cap (MIL)
41,753.02
Forward P/E
--
Dividend (Yield %)
6.59

Next Event

Bayer AG Split For BAY.BA - Ratio 3-1

Latest Developments

More

Bayer Submits Supplemental New Drug Application To FDA

Bayer's Phase 3 Study Chronos-3 In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma Meets Primary Endpoint

EU Gives Bayer Green Light For Full Launch Of Xtendflex Soybeans in 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bayer AG

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

Industry

Major Drugs

Contact Info

Kaiser-Wilhelm-Allee 1

51373

Germany

+49.214.301

https://www.bayer.de/

Executive Leadership

Norbert Winkeljohann

Chairman of the Supervisory Board

Werner Baumann

Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

Independent Vice Chairman of the Supervisory Board, Employee Representative

Wolfgang U. Nickl

Chief Financial Officer, Member of the Management Board

Liam Condon

Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit

Key Stats

2.24 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.0K

2018

39.6K

2019

43.5K

2020(E)

42.9K
EPS (EUR)

2017

6.633

2018

5.940

2019

6.400

2020(E)

6.501
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.96
Price To Book (MRQ)
1.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
115.73
LT Debt To Equity (MRQ)
95.08
Return on Investment (TTM)
-7.66
Return on Equity (TTM)
-5.77

Latest News

Latest News

Monsanto loses final appeal over French farmer's weedkiller accident

Bayer's <BAYGn.DE> Monsanto division on Wednesday lost a final appeal in a long-running French legal battle in which the crop chemical maker has been held liable for the accidental inhalation of a weedkiller by a crop farmer.

France clamps down on use of weedkiller glyphosate in farming

France's health and environment agency announced restrictions on weedkiller glyphosate in farming, but stopped short of a full ban in the European Union's top agricultural producer due to a lack of non-chemical alternatives in some areas.

Bleaker profit outlook at Bayer turns into reckoning over Monsanto

Bayer shares <BAYGn.DE> plunged after it flagged lower profit next year and warned it may have to write down the value of agriculture assets by close to 10 billion euros ($11.7 billion), rekindling a debate over the merits of the takeover of Monsanto.

Bayer plans more cost cuts, impairment charges

German drugs company Bayer AG <BAYGn.DE> announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024 and said it would take impairment charges on its agricultural business as it battles with low commodity prices.

Bayer to cut more than 1.5 bln euros in costs

German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

Bayer resolves more Roundup cases, judge keeps pause on litigation

Attorneys for Bayer AG and consumers suing the company over allegations its Roundup weedkiller caused cancer told a judge on Thursday they are continuing to resolve thousands more cases, improving prospects for its $11 billion deal to end the litigation.

Exclusive: In the weeds - How Bayer, U.S. government teamed up against Thailand's glyphosate ban

Chemicals giant Bayer and the U.S. government cooperated closely last year to lobby Thailand to reverse its ban on glyphosate, used in the company's controversial weedkiller Roundup, documents obtained by an environmental group and reviewed by Reuters show.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer in deal with Systems Oncology over novel breast cancer drug

Bayer said on Tuesday it had secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.

Bayer CEO's term extended, makes progress on Roundup settlement

Bayer boss Werner Baumann's contract has been extended until 2024, in a show of support from the drugmaker's new chairman just months after the company agreed an $11 billion outline settlement of U.S. lawsuits over its Roundup weedkiller.

Bayer appeals $20.5 million Roundup ruling to California Supreme Court

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer appeals $20.5 mln Roundup ruling to California Supreme Court

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Bayer acknowledges 'bumps' in $11 billion Roundup deal after judge raises doubts

Shares in German drugs company Bayer AG <BAYGn.DE> fell 3% on Friday after it said there were "bumps" in sealing its $11 billion settlement of U.S. lawsuits over its Roundup weed killer after a U.S. judge cast doubt on the progress of the agreement.

Bayer-Roundup $11 bln deal at risk of collapse, judge says - Bloomberg News

German drugs company Bayer AG's $11 billion settlement of thousands of U.S. lawsuits over its Roundup weed killer is less defined than the company disclosed, a judge overseeing the suits said, Bloomberg News reported on Thursday.

U.S. Black farmers seek ban or product warnings for Roundup weedkiller

A group of Black U.S. farmers filed a federal lawsuit on Wednesday, seeking to force Bayer AG to either stop selling its widely used weedkiller Roundup or roll out new product warnings.

Bayer to pay $1.6 billion to resolve U.S. claims for Essure birth-control device

German drugs and pesticides group Bayer <BAYGn.DE> said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

Bayer to pay $1.6 bln to resolve U.S. suits for Essure birth-control device

Bayer said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

9th Circ denies full court review of case that blocked dicamba sales

A federal appeals court has denied three en banc review petitions of a June ruling blocking Bayer AG and rivals from selling an agricultural weedkiller in the United States.

Bayer takes on Astellas in purchase of experimental menopause relief

Bayer <BAYGn.DE> moved to acquire a prospective non-hormonal menopause relief for an initial $425 million to strengthen its women's healthcare business, in a challenge to a similar development venture at Astellas <4503.T>.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up